RT Journal
A1 Stephenson J
T1 MIcrorna and liver cancer
JF JAMA
JO JAMA
YR 2009
FD November 18
VO 302
IS 19
SP 2083
OP 2083
DO 10.1001/jama.2009.1682
UL http://dx.doi.org/10.1001/jama.2009.1682
AB 
This cohort study, which involved a total of 455 patients, found that overall, those whose tumors had high levels of a microRNA called miR-26 lived about 4 years longer than those with low levels. A separate analysis, of miR-26 levels in liver tumor samples from participants in a trial that assessed response to adjuvant interferon α therapy, revealed that those whose tumors had normal miR-26 levels did not benefit from interferon. However, among patients whose tumors had low miR-26 expression (and a poorer prognosis), those who received interferon survived at least 7.7 years longer than those who did not.